Vyome Holdings

HIND

Market cap $15.2M

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated programs in areas of significant unmet medical need focused on.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are FDA-approved to treat a wid.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (“MFW”) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome,.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key anticipated benefits of an orphan drug designation include 7 years of U.S. market exclusivity, up to 25% of tax credits on clinical trials conducted in the USA, exemption from FDA Prescrip.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.